The overall aim of this project is to implement a non-invasive method of measuring quantitative regional cerebral blood flow (rCBF) on the UAB hybrid PET/MRI scanner to allow conducting such [O-15]water based scans with relative ease and safety in a large variety of important clinical and research applications. Participants will undergo imaging at baseline and after administration of a drug to increase cerebral blood flow to evaluate perfusion estimates during low and high flow states. The goal of this study is to generate data that will justify eliminating invasive arterial sampling in most [O-15]water-based PET protocols.

Start Date01 Feb 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

NCT06414759 / Not yet recruitingPhase 4IIT

Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload

This study aims to compare two medications, acetazolamide and metolazone, along with loop diuretics, to see which one works better and is safer for patients with ADHF who have volume overload. By comparing these medications, we hope to learn which one can help these patients the most. This will help doctors choose the best treatment for patients with ADHF and volume overload.

Start Date22 May 2024

Sponsor / Collaborator

Cairo University

[+1]

NCT06273397 / Not yet recruitingNot Applicable

Acetazolamide or Metolazone in Acute Heart Failure

Impact of Acute Heart Failure:
According to the World Health Organization (WHO), approximately 26 million people suffer from Heart Failure (HF), with a mortality rate of up to 50% within five years of diagnosis. Acute Heart Failure (AHF) exacerbations, leading to hospitalization, are common and represent the primary cause of hospital admissions in those over 65. Effective decongestion during hospitalization is crucial, as failure to achieve it doubles the risk of rehospitalization and mortality, incurring significant healthcare costs.
Use of Diuretics in Acute Heart Failure:
Diuretics, particularly loop diuretics like furosemide, are a cornerstone in managing AHF by inducing natriuresis and achieving decongestion. Clinical experience supports their use, though limited clinical trials exist. Pharmacological concepts guide their administration, emphasizing intravenous delivery in high doses and adjusting subsequent doses based on decongestive efficacy. Additionally, sequential tubular blockade with other diuretics like metolazone and acetazolamide is explored to enhance decongestion.
Use of Metolazone and Acetazolamide:
Sequential tubular blockade, using metolazone and acetazolamide in conjunction with furosemide, aims to achieve rapid and effective decongestion. While metolazone targets the distal tubule, inhibiting sodium-chloride channels, acetazolamide affects proximal tubular function. Studies like ADVOR (acetazolamide) and CLOROTIC (thiazide-like diuretic) demonstrate the potential benefits of combining these diuretics for quicker decongestion but with potential risks (in the case of Hydrochlorothiazide).
Outcomes Measured by Major Studies:
Recent studies assessing decongestion in AHF reveal a lack of uniformity in outcome selection. The primary focus should be on reducing rehospitalizations and post-discharge mortality by achieving effective decongestion. The ADVOR study, using a simple congestion score based on clinical and imaging criteria, underscores the importance of reaching a congestion score of 0 or 1 promptly.
Congestion Monitoring:
Monitoring diuretic treatment solely based on clinical aspects may not capture subclinical congestion, necessitating biochemical and imaging parameters. The ACME-AHF trial proposes a diagnostic score integrating clinical and imaging aspects to evaluate congestion status. Secondary outcomes include cumulative diuresis, weight loss, diuretic efficiency, and natriuresis, with a focus on natriuresis as a reliable physiological parameter for decongestion.
Aim of the study:
The ACME-AHF trial is designed to compare the efficacy and safety of two diuretic combination strategies: acetazolamide with furosemide and metolazone with furosemide. The primary objective is to relieve congestion, assessed using a congestion score, within the first three days of treatment during an hospitalization for acute heart failure.

Start Date01 May 2024

Sponsor / Collaborator

Clínica Alemana de Santiago SA

100 Clinical Results associated with Acetazolamide

100 Translational Medicine associated with Acetazolamide

100 Patents (Medical) associated with Acetazolamide

7,549

Literatures (Medical) associated with Acetazolamide

31 Dec 2024·Journal of enzyme inhibition and medicinal chemistry

Acetazolamide and human carbonic anhydrases: retrospect, review and discussion of an intimate relationship

Review

Author: Tsikas, Dimitrios

Acetazolamide (AZM) is a strong pharmacological sulphonamide-type (R-SO₂-NH₂, pK_a 7.2) inhibitor of the activity of several carbonic anhydrase (CA) isoforms, notably of renal CA II (K_i, 12 nM) and CA IV (K_i, 74 nM). AZM is clinically used for about eighty years in various diseases including epilepsy and glaucoma. Pharmacological AZM increases temporarily the urinary excretion of bicarbonate (HCO₃^-) and sodium ions (Na⁺) and sustainably the urinary pH. AZM is excreted almost unchanged over several hours at high rates in the urine. Closely parallel concentrations of circulating and excretory AZM are observed upon administration of therapeutical doses of AZM. In a proof-of-principle study, we investigated the effects of the ingestion of a 250-mg AZM-containing tablet by a healthy volunteer on the urinary excretion of organic and inorganic substances over 5 h (range, 0, 0.5, 1, 1.5, 2, 3, 4, 5 h). Measured analytes included: AZM, amino acids and their metabolites such as guanidinoacetate, i.e. the precursor of creatine, of asymmetrically (ADMA) and symmetrically (SDMA) dimethylated arginine, nitrite (O = N-O^-, pK_a 3.4) and nitrate (O₂N-O^-, pK_a -1.37), the major metabolites of nitric oxide (NO), the C-H acidic malondialdehyde (MDA; (CHO)₂CH₂, pK_a 4.5), and creatinine for correction of analytes excretion. All analytes were measured by validated isotopologues using gas chromatography-mass spectrometry (GC-MS) methods. AZM excretion in the urine reached its maximum value after 2 h and was fairly stable for the next 3 h. Time series analysis by the ARIMA method was performed. AZM ingestion increased temporarily the urinary excretion of the amino acids Leu + Ile, nitrite and nitrate, decreased temporarily the urinary excretion of other amino acids. AZM decreased sustainably the urinary excretion of MDA, a biomarker of oxidative stress (i.e. lipid peroxidation). Whether this decrease is due to inhibition of the excretion of MDA or attenuation of oxidative stress by AZM is unknown. The acute and chronic effects of AZM on the urinary excretion of electrolytes and physiological substances reported in the literature are discussed in depth in the light of its extraordinary pharmacokinetics and pharmacodynamics. Tolerance development/drug resistance to AZM in chronic use and potential mechanisms are also addressed.

01 Mar 2024·International journal of pharmaceutics

Development of direct compression Acetazolamide tablet with improved bioavailability in healthy human volunteers enabled by cocrystallization with p-Aminobenzoic acid

Article

Author: Roy, Sukanta ; Sun, Changquan Calvin ; Kumari, Nimmy ; Mondal, Susanta Kumar ; Roy, Parag ; Wang, Chenguang ; Ghosh, Animesh ; Das, Sourav ; Bose, Anirbandeep ; Pandey, Noopur

Pharmaceutical cocrystallization has been widely used to improve physicochemical properties of APIs. However, developing cocrystal formulation with proven clinical success remains scarce. Successful translation of a cocrystal to suitable dosage forms requires simultaneously improvement of several deficient physicochemical properties over the parent API, without deteriorating other properties critical for successful product development. In the present work, we report the successful development of a direct compression tablet product of acetazolamide (ACZ), using a 1:1 cocrystal of acetazolamide with p-aminobenzoic acid (ACZ-PABA). The ACZ-PABA tablet exhibits superior biopharmaceutical performance against the commercial tablet, DIAMOX® (250 mg), in healthy human volunteers, leading to more than 50 % reduction in the required dose.

01 Feb 2024·Drug and alcohol dependence

Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder

Article

Author: Ramey, Tatiana ; Gyaw, Shwe ; Devine, Eric G ; McCann, David J ; Chen, Hegang H

BACKGROUND:

Cocaine use disorder (CUD) is a major public health problem for which there is no approved pharmacotherapy. The primary purpose of this study was to evaluate the ability of lorcaserin, a 5-hydroxytryptamine_2 C (5-HT_2 C) receptor agonist, to facilitate abstinence in individuals seeking treatment for CUD.

METHODS:

This was a 12-site, randomized, parallel arm study with a 13-week Treatment Phase that included a 1-week, single-blind run-in period when all participants received twice daily 15mg acetazolamide capsules (a medication adherence marker), followed by randomization to either twice daily 10mg lorcaserin or placebo capsules for the remaining 12 weeks. Pre-randomization data were utilized in an enrichment strategy aimed at achieving high levels of medication adherence and low placebo response rates in a subgroup of participants that qualified for the "efficacy population." For lorcaserin vs. placebo, the primary efficacy endpoint was the proportion of participants in the efficacy population achieving abstinence during the last three weeks of treatment, as evidenced by self-report of no cocaine use, confirmed by urine testing.

RESULTS:

Within the efficacy population, 1.1% of 91 participants receiving lorcaserin and 4.3% of 92 receiving placebo achieved abstinence during the last 3 weeks of treatment. Among all randomized participants, 2.5% of 118 receiving lorcaserin and 5.6% of 124 receiving placebo achieved similar abstinence. Study participants receiving lorcaserin exhibited significantly greater reductions in body weight and BMI, indicating that medication adherence was sufficient to produce a pharmacological effect.

CONCLUSIONS:

Twice daily 10mg lorcaserin failed to demonstrate efficacy in the treatment of CUD.

News (Medical) associated with Acetazolamide

03 Jun 2024

·www.biospace.com

Obsidian Therapeutics Announces Additional OBX-115 Safety and Efficacy Data in Oral Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

OBX-115 continues to demonstrate a positively differentiated safety pro to IL2-dependent non-engineered TIL cell therapy: no DLTs, no Grade 4 or higher non-hematologic TEAEs observed. OBX-115 efficacy pro in additional patients, including a 44% ORR with 2 CRs (n=9), and a 50% ORR in patients receiving cell dose >30 × 109 cells. Emerging survival and PFS data are promising, with no treatment- or disease-related mortality (OS 100%, median study follow-up of 29.5 weeks) and PFS of 75% at 24 weeks. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Obsidian Therapeutics Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced updated data from the ongoing Phase 1 first-in-human, dose-escalation study of OBX-115, a novel engineered tumor-derived autologous T-cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma. These data were presented in an oral presentation delivered by Rodabe Amaria, M.D., professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center and principal investigator of the study, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The oral presentation for the single-center study (NCT05470283) included a 3-month incremental data update (relative to published abstract) on safety (N=10) and efficacy (n=9 per-protocol efficacy analysis set) for patients with advanced or metastatic melanoma. Summary of OBX-115 Safety and Efficacy Data (April 4, 2024 data cutoff): OBX-115 Exhibits Positively Differentiated Safety Pro to IL2-Dependent Non-Engineered TIL Cell Therapy: All 10 infused patients were alive at data cutoff (median study follow up of 29.5 weeks). No patient received care in the intensive care unit. No dose-limiting toxicities were observed at any dose level. No Grade 4 or higher non-hematologic treatment-emergent adverse events (TEAEs) were reported; 2 patients experienced limited Grade 3 non-hematologic TEAEs. No confirmed events of cytokine release syndrome, capillary leak syndrome, or immune effector cell-associated neurotoxicity syndrome were reported. OBX-115 Sustains Consistent Efficacy Profile, without IL2 Administration, in Patients with Substantially Pre-Treated Resistant/Refractory Disease: Patients had disease that was predominantly ICI primary-resistant, with a median of 3.5 (range, 1–6) lines of prior systemic therapy, including a median of 2 (1–3) lines of prior ICI therapy. 44% objective response rate (ORR), including 2 complete responses (CRs), using investigator-assessed RECIST 1.1 criteria across all doses (n=9 per-protocol efficacy analysis set). 50% ORR in patients who received OBX-115 dose of >30 × 109 cells (n=6). 100% disease control, defined as CR, PR, or ≥12-week duration of stable disease post OBX-115 infusion. Progression-free survival (PFS) was 75% at 24 weeks. Tumor burden reduction in all 9 patients, including several with tyrosine kinase inhibitor (TKI)-refractory disease and / or prior treated brain metastasis. Disease control and responses observed with both fresh and cryopreserved OBX-115 product. Additional OBX-115 Data Contributing to an Optimized Cell Therapy Product: Robust manufacturing process observed for OBX-115, including from tumor tissue obtained using core needle biopsy. Median manufactured OBX-115 dose (N=10): 100 × 109 cells. Translational data highlight that the OBX-115 infusion product is optimized for response and persistence: predominantly CD8+ cytotoxic T-cell population, effector memory phenotype, high proportion of CD8+CD39-CD69- (double-negative) “stem-like” progenitor cells and low levels of exhaustion markers. Dr. Amaria commented, “OBX-115 continues to demonstrate positive safety and efficacy data in additional patients, which is encouraging, given this is a heavily pre-treated patient population with advanced disease. Unfortunately, late-line systemic therapy options offer limited benefit, with ORR of approximately 10% and mPFS of approximately 2–3 months. It is exciting to see a potential new option emerge for these patients with a positively differentiated safety pro promising early activity achieved without IL2.” “We believe OBX-115 has the potential to advance the TIL cell therapy field in multiple ways, including enabling non-surgical tumor tissue procurement and abrogating the need for IL2. We are also exploring the ability to re-energize engrafted OBX-115 cells with acetazolamide re-dosing,” commented Parameswaran Hari, M.D., Chief Development Officer of Obsidian. “We look forward to continuing to build on this momentum and apply key learnings from the first-in-human Phase 1 study to our ongoing Phase 1/2 multicenter study, where we are continuing to explore these attributes and optimize the OBX-115 regimen in melanoma and non-small cell lung cancer.” Obsidian is actively enrolling patients with advanced or metastatic melanoma and non-small cell lung cancer (NSCLC) at multiple sites in its ongoing Phase 1/2 multicenter study. Additional details may be found at clinicaltrials.gov, using identifier: NCT06060613. About OBX-115 Obsidian’s lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian’s proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. OBX-115 is being investigated in two ongoing clinical trials in advanced or metastatic melanoma and NSCLC (NCT05470283 and NCT06060613). About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit obsidiantx.com and follow us on LinkedIn.

Clinical ResultPhase 1Cell TherapyASCOImmunotherapy

04 Apr 2024

·www.pharmaceutical-technology.com

Obsidian raises $160.5m to advance TIL cell therapy programme

TIL therapy uses naturally occurring immune cells that detect and attack cancer cells. Image credit: Shutterstock/Christoph Burgstedt. Obsidian Therapeutics has raised $160.5m in a Series C financing round, with plans for the funds to be injected into the biotech’s tumour-infiltrating lymphocyte (TIL) cell therapy programme. Obsidian, already backed by Bristol Myers Squibb (BMS), added Novo Nordisk Foundation’s investment arm Novo Holdings to its arsenal of investors in this latest round. US investment firm Wellington Management led the oversubscribed Series C. The US biotech previously raised $115m in a Series B round in 2021. Obsidian’s lead asset is OBX-115 , which is part of its TIL programme. OBX-115 is a TIL cell therapy – which expands and enhances the patient’s own immune cells extracted from around and within the tumour itself. Unlike the emerging chimeric antigen receptor (CAR) T cell therapies , TILs already have multiple tumour target recognition. The T cell immunotherapy is in a Phase I clinical trial for the treatment of melanoma and a Phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC). In the melanoma trial (NCT05470283), which is being sponsored by the MD Anderson Cancer Centre, OBX-115 is being administered in combination with the diuretic acetazolamide. Data from the study will inform dose levels for a Phase II trial. The company reported an objective response rate of 50% and a complete response rate of 33% in topline data released in December 2023. See Also: Seaport emerges after $100m raise with ex-Karuna team at helm Pluri launches manufacturing division as cell therapy pipeline progresses The NSCLC trial (NCT06060613) is investigating OBX-115 as a monotherapy, with endpoints assessing the drug’s safety and efficacy in treating advanced solid tumours. Obsidian said the Series C proceeds will go towards clinical trial activities and manufacturing scale-up with a view to conducting pivotal trials. Obsidian has engineered OXB-115 such that it produces the membrane-bound interleukin 15 (IL-15). Interleukin-2 (IL-2) co-administration is usually needed with traditional TIL cell therapies to act as an immunostimulatory agent. Obsidian states that the membrane-bound IL-15 could widen patient access by reducing potential toxicities associated with high-dose IL-2. Vertex and BMS have seen the potential in Obsidian’s platform, both signing multi-year partnerships with the biotech to discover and develop new cell therapies. Last month, Iovance Biotherapeutics ’ Amtagvi (lifileucel) became the first TIL cell therapy to get regulatory backing in the US, winning a US Food and Drug Administration (FDA) accelerated approval. Obsidian’s OBX-115 will face competition from Iovance, with Amtagvi indicated for the treatment of metastatic or unresectable melanoma. Iovance has priced its immunotherapy at $515,000 in a market where there are currently no other FDA-approved cell therapies for the treatment of solid tumours. Amtagvi is forecast to generate sales of $846m by 2029, according to GlobalData’s Pharma Intelligence Centre. GlobalData is the parent company of Pharmaceutical Technology. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

Cell TherapyPhase 1ImmunotherapyClinical ResultGene Therapy

03 Apr 2024

·firstwordpharma.com

On the heels of first TIL approval, Obsidian clinches $160M to make the modality safer

As cell therapies for solid tumours have struggled to reach the efficacy bar set in haematologic malignancies, tumour-infiltrating lymphocytes (TILs) have finally found a foothold – but require co-dosing with a risk-riddled systemic cytokine therapy. Obsidian Therapeutics, which raised a $160.5-million series C on Wednesday, is engineering a TIL therapy with the necessary cytokine stimulation already built-in, eliminating the need for an additional, potentially harmful infusion.The round, led by new investor Wellington Management, will go towards enrolling more patients in Obsidian’s ongoing early-stage studies of its engineered TIL therapy, dubbed OBX-115, in patients with melanoma and non-small-cell lung cancer (NSCLC). The funding will also help scale up the company’s manufacturing capabilities ahead of pivotal trials.Solid tumour hurdleDue to their polyclonal nature, TILs stand to succeed in solid tumours where CAR-T and T-cell receptor (TCR) cell therapies have struggled, Obsidian chief executive Madan Jagasia told FirstWord.“Compared to haematologic malignancies, solid tumours have fewer clinically-validated tumour-specific neoantigen targets that are shared across patients, which limits the applicability for CAR-Ts and TCR-Ts that are engineered to target a specific tumour antigen,” he explained. TILs, on the other hand, “can naturally recognize multiple neoantigens and therefore overcome single-antigen escape mechanisms.” In February, the FDA approved Iovance’s Amtagvi (lifileucel) as the first TIL therapy to treat certain forms of melanoma.However, to effectively combat cancer, the TIL therapy requires a near-simultaneous administration of the T-cell growth cytokine IL-2 to support the expansion, persistence, and activity of the cells in vivo. According to Jagasia, systemic IL-2 can lead to severe toxicities including capillary leak syndrome (CLS), myocardial infarction, acute renal failure and immune-mediated neuropathy. Indeed, Amtagvi carries a boxed warning for treatment-related mortality. Obsidian aims to eliminate the need for concurrent IL-2 treatment by arming its TILs with membrane-bound IL-15. Using its cytoDRiVE platform, Obsidian packages and inserts a gene cassette encoding IL-15 tagged with a drug-responsive domain (DRD) into the patient-derived cells. After infusion, the cells then produce IL-15 fused to the DRD, which can only be stabilised for membrane-bound expression in the presence of acetazolamide, an FDA-approved small molecule commonly used as a diureticOnce patients receive acetazolamide, TIL expansion is triggered – all without requiring IL-2. Additionally, Jagasia said that the engineered therapy are less exhausted cells with enrichment for CD8+ T-cells.

Drug ApprovalGene TherapyCell Therapy

100 Deals associated with Acetazolamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00218	Acetazolamide	S01EC01	DB00819

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pre-Eclampsia	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	02 Jun 1994
Sleep Apnea Syndromes	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1988
Ocular Hypertension	CN	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1983
Acidosis, Respiratory	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Glaucoma	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Meniere Disease	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Premenstrual Syndrome	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Endocrinology and Metabolic Disease	US	Teva Women's Health, Inc.	25 Jun 1954
Acute angle-closure glaucoma	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953
Altitude Sickness	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953
Edema	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953
Epilepsy	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953
Glaucoma, Open-Angle	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953
Secondary glaucoma	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04639193 (CTgov)	Phase 2	Sleep Apnea, Obstructive	20	Acetazolamide+Eszopiclone (Dual-Therapy)	yitmaxogwm(eerktclrgk) = lassitvmzo wriopumybn (mgltuuxmhq, fmiidwwvfq - ltpzanwgje) View more	-	02 May 2024
				Placebo+Acetazolamide+Eszopiclone (Placebo)	yitmaxogwm(eerktclrgk) = wvhtyksxxs wriopumybn (mgltuuxmhq, ibdjbcsotd - zbylwthnfw) View more
CNS2023	Not Applicable	Status Epilepticus Second line	-	Acetazolamide (AZM)	wysagqbxdu(fguacufjqq) = plkkblqevy ewwphxqhqw (hzqbnyqyda )	-	01 Oct 2023
				Benzodiazepine - diazepam or clobazam	wysagqbxdu(fguacufjqq) = ryaaiaforz ewwphxqhqw (hzqbnyqyda )
NCT03505788 (ADVOR Trial, Pubmed)	Phase 4	Acute decompensated heart failure	519	Acetazolamide	sqhllxmrft(rhajrklvoo) = mqqxqmaran mtebwsmoik (hejanemypq )	-	25 Aug 2023
				Placebo	sqhllxmrft(rhajrklvoo) = mlionvqrzg mtebwsmoik (hejanemypq )
NCT03377049 (CTgov)	Phase 4	Ischemia \| Aneurysm, Intracranial Berry, 1 \| Vasospasm, Intracranial	11	Acetazolamide	krpkesawgh(xvjnoqrjlj) = pmsunkcqtm hkbwhfggcp (jhpwyzlojc, duyasdaerv - ikhpoehzdq) View more	-	27 Jul 2023
NCT03505788 (ADVOR, Pubmed)	Phase 4	Volume overload \| Acute decompensated heart failure	519	Acetazolamide	sdgaigyjpb(fdagfyfrcj) = pelsawexiw wgctkrkauu (zwxpcahqby ) View more	-	23 May 2023
ADVOR trial (ESC2023)	Not Applicable	-	519	Acetazolamide	zfcfssqdet(kkcqdtxxks) = kpdhsqlecn lgtdeqcurh (ncthtgyusw ) View more	-	21 May 2023
				Placebo	zfcfssqdet(kkcqdtxxks) = tcpdmjtmod lgtdeqcurh (ncthtgyusw ) View more
NCT02466074 (CTgov)	Phase 2	Multiple Sclerosis	5	Acetazolamide (Acetazolamide)	mnxprhifrq(cwozzcgovz) = ullrkmkogf ifrnccfqht (vvhcnwinrd, nlmyfvaaho - wosivgctil) View more	-	01 Mar 2023
				Placebo (Placebo)	qucjvqomti(vxkxtbpodz) = nqrnumstav ohmsiiftgt (tyflrvpplw, zuldhvougi - bpfjzagypl) View more
NCT05290948 (Pubmed)	Phase 2	Retinal vein occlusion-related macular edema	54	IVB and OA combination therapy	aquzhjvduc(xrmnvcpoly) = gecavfqbti qmofytilsh (eaduxgwljy ) View more	-	02 Feb 2023
				IVB monotherapy	aquzhjvduc(xrmnvcpoly) = xcvrskfrqv qmofytilsh (eaduxgwljy ) View more
NCT02755298 (Pubmed)	Phase 2/3	Pulmonary Vascular Disease	28	Acetazolamide	modihfrinm(xxxrqvltxn) = pneydldwhd bkpplbcfuf (yvrvcljlig )	Negative	11 Jan 2023
AAIC2022	Not Applicable	Alzheimer Disease	-	Acetazolamide 125 mg	snlmxgkpjr(smayicdhmb) = kpzythdvvy vxqxsfoqxy (pchncoiesj ) View more	Positive	20 Dec 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis